Oncology Data Advisor® · Taking the Stage for Patient Advocacy With Megan-Claire Chase Megan-Claire Chase, a patient advocate and invasive lobular breast cancer survivor, recently appeared on the "Beyond Cancer" Episode of PBS's Stories from the Stage. In this interview, Ms. Chase shares more about the experience and the important messages for patients, survivors, and clinicians that she hoped to convey in her talk and throughout her advocacy. Oncology Data Advisor: Welcome to ...
At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Megan-Claire Chase, breast cancer survivor and Breast Cancer Program Director at SHARE Cancer Support, sat down with Oncology Data Advisor to talk about her diagnosis, treatment, and survivorship journey, as well as her advocacy work to empower people living with cancer.
This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed.
At the recent 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Darya Kizub, Hematology-Oncology Fellow at MD Anderson Cancer Center, presented her team's research regarding a novel initiative for recruiting Black individuals to be screened for hereditary cancer genetic testing eligibility. Prior to presenting, she sat down with Oncology Data Advisor to share more about the need to provide cancer genetic testing for Black individuals and the ways that she and her team have partnered with the community to enact this change.
In 2006, after being diagnosed with breast cancer at the age of 32, Maimah Karmo decided to dedicate herself to empowering women with breast cancer to serve as advocates for themselves, resulting in the creation of Tigerlily Foundation. In this interview, Ms. Karmo shares more of her story and her passion for amplifying the patient's voice, increasing awareness of and access to screening, ending disparities for underserved communities, and emboldening nurses to champion breast cancer care for th...
Eun-Ok Im, PhD, MPH, RN, CNS, FAAN, was recently named as the recipient of the 2023 Oncology Nursing Society (ONS) Distinguished Nurse Researcher Award. At this past ONS Congress, Dr. Im gave a presentation on her pioneering use of technology and Internet-based approaches to address racial and ethnic survivorship disparities in the cancer survivorship experience, which she has been among the first to research over the course of her career. In this interview, she provides the background behind this approach and how it has been used to improve survivorship experience for racial/ethnic minority cancer patients.
Oncology Data Advisor® · Social Media’s Effect on Informed Decision Making in Cancer Treatment Welcome to Oncology Data Advisor®, a digital resource for the multidisciplinary cancer team. In this podcast episode, Nina Morena, MA, PhD Candidate at McGill University, and Ari Meguerditchian, MD, Surgical Oncologist at McGill University Health Center, sit down to talk about Ms. Morena's thesis topic and research, How reliable are post-mastectomy breast reconstruction videos on YouTu...
Phosphatidylinositol-3-kinase (PI3K) inhibitors are effective treatment for patients with breast cancer but can be associated with significant hyperglycemia and rash. In this interview from the 48th Annual Oncology Nursing Society (ONS) Congress, Janie Metsker, RN, BSN, CN-BN, Clinical Coordinator at St. Luke's Koontz Center for Advanced Breast Cancer, shares updated strategies for managing these toxicities in order to provide the best outcomes for patients with breast cancer receiving PI3K inhibitors.
The FDA has granted approval to sacituzumab govitecan-hziy (Trodelvy®, Gilead Sciences, Inc.) for treatment of unresectable, locally advanced, or metastatic hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer. Patients are required to have received at least one prior line of endocrine therapy and two systemic therapies in the metastatic setting. "Sacituzumab govitecan is a first-in-class trophoblast cell-surface antigen 2 (Trop-2)–directed antib...
The FDA has approved elacestrant (Orserdu™, Stemline Therapeutics, Inc.) for postmenopausal women or adult men with estrogen receptor (ER)–positive, human epidermal growth factor receptor 2 (HER2)–negative, estrogen receptor 1 (ESR1)–mutated advanced or metastatic breast cancer with disease progression subsequent to at least one line of endocrine therapy. Additionally, the FDA approved the Guardant360 CDx assay, a companion diagnostic test, to identify breast cancer patients eligible for treatme...
In this latest Breast Cancer Awareness Month interview, Dr. Elizabeth Stirling Craig, Director of Microvascular Breast Reconstruction at St. Vincent's Medical Center of Hartford HealthCare, explains the microsurgical techniques that she performs as a breast reconstructive surgeon and shares the importance of providing patients with a clear picture of the reconstructive options that are available to them.
At the recent San Antonio Breast Cancer Symposium (SABCS), Yara Abdou, MD, Assistant Professor of Hematology and Oncology and Medical Oncologist at The University of North Carolina School of Medicine, presented her team's research on the disparities that Black women with breast cancer experience. Afterwards, she spoke with Oncology Data Advisor to go into further detail on her findings, as well as to answer a few questions regarding future clinical trials and research to explore disparities Blac...
An educational activity provided by i3 Health has delivered significant improvement in knowledge regarding treatment advances and personalized care for patients with metastatic triple-negative breast cancer (TNBC). Breast cancer is the most commonly diagnosed cancer and the second-leading cause of cancer-related death among women in the United States. Approximately 15% of cases are classified as triple-negative, lacking expression of estrogen, progesterone, and human epidermal growth factor 2 (H...
In this interview, Dr. Jason Mouabbi speaks with Oncology Data Advisor about his research regarding the absence of lobular carcinoma in situ as a poor prognostic marker in invasive lobular carcinoma, which will be presented as a poster at the 2022 San Antonio Breast Cancer Symposium (SABCS).
Understanding the various subtypes of breast cancer is critical, as treatment selection and potential outcomes depend heavily on subtype. In this latest Oncology Data Advisor interview for Breast Cancer Awareness Month, Dr. Jason Mouabbi, an Assistant Professor at the University of Texas MD Anderson Cancer Center, sheds light on lobular breast, an often-understudied subtype. Dr. Mouabbi shares his passion for raising awareness about lobular breast cancer and his goal of better understanding it at the genomic level to develop novel therapeutic options.
In this interview with Oncology Data Advisor, Dr. Samuel Kareff, a Hematology-Oncology Fellow at Sylvester Comprehensive Cancer Center of the University of Miami, provides a comprehensive overview of the current and emerging therapies used in the treatment of breast cancer, serving as a valuable resource to share with patients who may be discussing these options with their oncology team.
Recently, Oncology Data Advisor hosted a live faculty panel discussion in advance of ODACon™ 2022 Supportive Care Summit: Managing Toxicities of Novel Breast Cancer Therapies, featuring the conference's four expert nurse speakers: Dr. Constance Visovsky, Abbey Kaler, Julia LaBarbera, and Janie Metsker. In their conversation, they gave a preview of the educational topics they'll be covering at ODACon on November 12, as well as highlighting their individual research interests and their work in the...
In honor of Breast Cancer Awareness Month, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare, spoke with Oncology Data Advisor to raise awareness about the reality that men can get breast cancer too. Dr. Brutus explains the risk factors and the conversations that men can have with their health care providers to understand their individual risks for breast cancer.
In honor of Breast Cancer Awareness Month, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare, spoke with Oncology Data Advisor to raise awareness about the reality that men can get breast cancer too. Dr. Brutus explains the risk factors and the conversations that men can have with their health care providers to understand their individual risks for breast cancer.
In honor of Breast Cancer Awareness Month, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare, spoke with Oncology Data Advisor about the risks for breast cancer in transgender individuals. Dr. Brutus shares the importance of starting the conversation about individualized risk assessment to provide the most appropriate screening recommendations and personalized care for every patient.
In honor of Breast Cancer Awareness Month, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare, spoke with Oncology Data Advisor about the risks for breast cancer in transgender individuals. Dr. Brutus shares the importance of starting the conversation about individualized risk assessment to provide the most appropriate screening recommendations and personalized care for every patient.